SUPER IMPRESSIVE: pancreatic cancer just got its most meaningful survival improvement
daraxonrasib vs chemotherapy:
- 13.2 months median survival vs 6.7 months
- 53% of patients alive at 12 months vs 17%
- hazard ratio 0.40. that means a 60% reduction in the risk of death
but here is what's even more impressive
RAS mutations drive 30% of all human cancers. lung, colon, pancreatic. the most common and the deadliest. RAS has been called undruggable for 40 years. Revolution Medicines just drugged it
an oral pill. once daily. FDA Breakthrough Therapy designation and it's being presented at ASCO this week
that is what happens when you combine precision genomics, targeted therapy design, and the audacity to go after the target everyone said was impossible
the era of cancer as a death sentence is soon ending
bio/acc
Many people spent a career in relative obscurity to deliver a breakthrough result in cancer care today. Hoping this drug gets to all the patients that need it as soon as possible/yesterday.